Clients without insurance are eligible to receive Truvada® free of charge from Gilead's Patient Assistance Program. The PrEP-AP will only provide assistance with PrEP-related medical costs, and all other medication on the PrEP-AP formulary for the prevention of HIV and treatment of sexually transmitted infections (STIs). Please Note: Uninsured clients must receive PrEP-related medical services at approved locations within OA's PrEP-AP Provider Network. DOWNLOAD MORE INFORMATION HERE. (Español)
Clients with Private Insurance
Clients with private health insurance are eligible for PrEP medication co-payment assistance of $7,200 per calendar year through Gilead's Co-Payment Assistance Program. After this threshold has been met, the PrEP-AP will provide wrap-around coverage for any remaining PrEP medication co-payments for the remainder of calendar the year. Insured clients can enroll in Gilead's Co-Payment Assistance Program online or through an authorized ADAP Enrollment Site. The PrEP-AP will also provide assistance with PrEP-related medical out-of-pockets costs for insured clients and all other medication on the PrEP-AP formulary for the prevention of HIV and treatment of STIs. DOWNLOAD MORE INFORMATION HERE.
Clients with Medicare
Clients with prescription drug coverage through Medicare are not eligible for assistance from Gilead, but are eligible to enroll in the PrEP-AP for co-payment assistance for all medication on the PrEP-AP formulary, including Truvada®. Medicare clients without prescription drug coverage are eligible to enroll in the Gilead PAP to receive Truvada® free of charge. The PrEP-AP will provide assistance with all other medications on the PrEP-AP formulary. Please Note: All Medicare clients with outpatient coverage through Medicare are eligible to receive assistance with PrEP-related medical out-of-pocket costs. DOWNLOAD MORE INFORMATION HERE.
PrEP means Pre-Exposure Prophylaxis, and it’s the use of anti-HIV medication that keeps HIV negative people from becoming infected. PrEP is approved by the FDA and has been shown to be safe and effective. A single pill taken once daily, it is highly effective against HIV when taken every day. The medication interferes with HIV’s ability to copy itself in your body after you’ve been exposed. This prevents it from establishing an infection and making you sick.
Even though PrEP has been around in the U.S. for over a year, not a lot of people know about it. And, even fewer people feel like they know enough about it to be able to make an informed decision about whether or not to use it. For those who do use it, the information they have might be more focused on practical issues, like where to get it, rather than on what PrEP does in the body to prevent HIV infection.
By using animation to show PrEP in the body and why “once a day” is recommended, people can see what PrEP does and people who currently use PrEP can create an image of what happens when they take a PrEP pill every day. See CDC 2017 Clinical Practice Guidelines HERE
Addressing PrEP Disparities among Young Gay & Bisexual Men in CA
Executive Summery by The California HIV/AIDS Research Program
Young gay, bisexual, and other men who have sex with men (YMSM), particularly black and Latino YMSM, are at highest risk for HIV in California and across the United States. The Centers for Disease Control and Prevention estimates that if current rates persist, half of all black—and a quarter of all Latino—gay and bisexual men could be infected with HIV in their lifetimes. Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention intervention that could drastically reduce the number of new HIV infections among YMSM. PrEP uses a well-established antiretroviral medication, Truvada, to block HIV infection in at-risk HIV-negative individuals. When taken as prescribed, Truvada is proven to be over 90 percent effective at preventing HIV. Recent studies have shown PrEP awareness and uptake to be low among at-risk populations in California and across the United States for a number of reasons, including concerns about side effects, perceived high cost, limited access, and PrEP-related stigma. If barriers to PrEP use among YMSM are not addressed, the benefits of this HIV prevention strategy will not be fully realized.
About 1 in 10 respondents reported having used PrEP (9.6%). The majority (90.3%) of respondents were PrEP naïve, never having used PrEP. PrEP use was significantly higher among white respondents (13.9%) compared to Latino respondents (6.6%). PrEP use among black respondents was 9.8%, though not significantly different from white and Latino respondents. PrEP use was significantly higher among 22–25 year olds (14.0%) and 26–29 year olds (9.3%) compared to PrEP use among 18–21 year olds (3.9%). PrEP use was significantly higher among respondents with annual incomes of $30,000 or higher (13.0%) compared to PrEP use among respondents with annual incomes of $29,000 or less (9.9%).